GC remains the fourth most common cancer and is second leading cause of cancer-related death worldwide, exceeded only by lung cancer. Received 7 October 2015 accepted 1 January 2016 published 4 January 2016 Subtype of GC for enrolment, and in selecting patients according to prognosticįactors to optimize the benefits of chemotherapy. Regional, racial or molecular characteristics, to consider the molecular Implementing strategies in which patients are selected on the basis of Patients from LA are under-represented in multicenter trials ofĬhemotherapy and targeted therapies.
This review examines studies conducted in Oxaliplatin or irinotecan with fluoropyrimidineĬan also be used in elderly patients who are not candidates for cisplatin, or Standard of care in light of the findings of phase III studies, whileĭocetaxel, cisplatin, and 5-fluorouracil (5-FU) are alternatives for patients Cisplatin and fluoropyrimidine continue to be the However, the best regimen for specific populations, suchĪs LA, is as yet unknown. Chemotherapy is the standard treatmentįor advanced-stage GC. Latin America (LA), the burden of this disease is higher and is the leadingĬause of cancer death in some countries. Neoplasm and the second leading cause of cancer-related death worldwide. Gastric cancer (GC) is the fourth most common
0 kommentar(er)
